Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note released on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $2.00 target price on shares of Aptose Biosciences in a research report on Friday, January 10th.

Aptose Biosciences Price Performance

Shares of APTO stock opened at $0.21 on Thursday. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.30. The company’s fifty day moving average price is $0.23 and its 200-day moving average price is $0.38. The company has a market capitalization of $12.87 million, a price-to-earnings ratio of -0.07 and a beta of 0.87.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC acquired a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned about 9.46% of Aptose Biosciences at the end of the most recent reporting period. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.